Abstract
Epithelial cells are covered in carbohydrates. This glycan coat or “glycocalyx” interfaces directly with microbes, providing a protective barrier against potential pathogens. Bacterial vaginosis is a condition associated with adverse health outcomes in which bacteria reside in direct proximity to the vaginal epithelium. Some of these bacteria, including Gardnerella, produce glycosyl hydrolase enzymes. However, glycans of the vaginal epithelial surface have not been studied in detail. Here we elucidate key characteristics of the vaginal epithelial glycan landscape and determine the impact of resident microbes on the surface glycocalyx. In BV, the glycocalyx was visibly diminished. We show that the “normal” vaginal epithelium displays sialylated N- and O-glycans by biochemical and mass spectrometric analysis. In contrast, BV-epithelial cell glycans were strikingly depleted of sialic acids, with underlying galactose residues exposed on the surface. Treatment of cells from BV-negative women with recombinant Gardnerella sialidases generated BV-like glycan characteristics. Together these data provide the first evidence that the vaginal epithelial glycocalyx is attacked by hydrolytic enzymes in BV. Given the widespread structural and functional roles of sialoglycans in biology and disease, these findings may point to a shared epithelial pathophysiology underlying the many adverse outcomes associated with BV.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was funded by the National Institute of Allergy and Infectious Diseases (R01 AI114635 to ALL and WGL, R01 AI127554 to WGL), the Burroughs Wellcome Fund Preterm Birth Initiative (to ALL). This work was also supported by the Stephen I. Morse fellowship to K.A. (Department of Molecular Microbiology, Washington University in St. Louis, MO, USA). Funding for the Contraceptive CHOICE Project was provided by an anonymous foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was reviewed and approved by the Institutional Review Board at Washington University School of Medicine (IRB ID # 201108155).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
